Vericel (VCEL) Other Non-Current Liabilities (2010 - 2026)
Vericel (VCEL) posted Other Non-Current Liabilities of $1.9 million for Q2 2026, up 1.86% sequentially from $1.9 million in Q1 2026, and up 15.58% YoY from $1.7 million in Q2 2025.
Analysis
Vericel (VCEL) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Vericel has reported Other Non-Current Liabilities for 17 years, with the latest figure at $1.9 million in Q2 2026.
- Quarterly Other Non-Current Liabilities rose 15.58% year-over-year to $1.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.9 million (up 15.58% YoY) and the FY2025 annual result came in at $1.9 million, up 116.44% from the prior year.
- Other Non-Current Liabilities advanced to $1.9 million in Q2 2026 per VCEL's latest filing, from $1.9 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $1.9 million in Q2 2026 and troughed at $19000.0 in Q1 2022.
- A 5-year average of $838000.0 and a median of $243000.0 in 2024 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities sank 66.67% in 2022, then surged 1100.0% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $21000.0 in 2022, then soared by 376.19% to $100000.0 in 2023, then surged by 776.0% to $876000.0 in 2024, then surged by 116.44% to $1.9 million in 2025, then rose by 0.95% to $1.9 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $1.9 million, $1.9 million, and $1.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.91 Mn |
| Mar 31, 2026 | 1.88 Mn |
| Dec 31, 2025 | 1.90 Mn |
| Sep 30, 2025 | 1.67 Mn |
| Jun 30, 2025 | 1.66 Mn |
| Mar 31, 2025 | 1.85 Mn |
| Dec 31, 2024 | 876,000.00 |
| Sep 30, 2024 | 243,000.00 |
| Jun 30, 2024 | 198,000.00 |
| Mar 31, 2024 | 154,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Sep 30, 2023 | 65,000.00 |
| Jun 30, 2023 | 28,000.00 |
| Jun 30, 2022 | 21,000.00 |
| Mar 31, 2022 | 19,000.00 |
| Dec 31, 2021 | 44,000.00 |
| Sep 30, 2021 | 42,000.00 |
| Jun 30, 2021 | 62,000.00 |
| Mar 31, 2021 | 57,000.00 |
| Dec 31, 2020 | 76,000.00 |